{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T22:30:07Z","timestamp":1786487407731,"version":"build-2736575974"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100016109","name":"Taishan Industry Leading Talents","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100016109","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmaceutical Science Advances"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.pscia.2026.100136","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T07:05:29Z","timestamp":1784790329000},"page":"100136","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Development and characterization of an Indacaterol\/Tiotropium Bromide composite dry powder inhalation formulation for COPD"],"prefix":"10.1016","volume":"4","author":[{"given":"Xiaobing","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunlei","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenkun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuwen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihua","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianhai","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weijian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.pscia.2026.100136_bib1","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1183\/09031936.06.00124605","article-title":"Global burden of COPD: systematic review and meta-analysis","volume":"28","author":"Halbert","year":"2006","journal-title":"Eur. Respir. J."},{"issue":"B","key":"10.1016\/j.pscia.2026.100136_bib2","article-title":"Canadian thoracic society recommendations for management of chronic obstructive pulmonary disease \u2013 2007 update","volume":"14","author":"O'Donnell","year":"2007","journal-title":"Can. Respir. J. J. Can. Thorac. Soc."},{"issue":"3","key":"10.1016\/j.pscia.2026.100136_bib3","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/resp.13012","article-title":"Global strategy for the diagnosis, management and prevention of chronic obstructive lung disease 2017 report","volume":"22","author":"Vogelmeier","year":"2017","journal-title":"Respirology"},{"issue":"1","key":"10.1016\/j.pscia.2026.100136_bib4","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1186\/s12913-016-1482-7","article-title":"The economic burden of asthma and chronic obstructive pulmonary disease and the impact of poor inhalation technique with commonly prescribed dry powder inhalers in three European countries","volume":"16","author":"Lewis","year":"2016","journal-title":"BMC Health Serv. Res."},{"issue":"6","key":"10.1016\/j.pscia.2026.100136_bib5","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14061185","article-title":"State of the art in capsule-based dry powder inhalers: deagglomeration techniques and the consequences for formulation aerosolization","volume":"14","author":"Gro\u00df","year":"2022","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.pscia.2026.100136_bib6","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40248-017-0092-5","article-title":"Recent advances in capsule-based dry powder inhaler technology","volume":"12","author":"Lavorini","year":"2017","journal-title":"Multidiscip. Respir. Med."},{"issue":"4","key":"10.1016\/j.pscia.2026.100136_bib7","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1089\/jamp.2024.29117.mk","article-title":"Inhaled nanoparticulate systems: composition, manufacture and aerosol delivery","volume":"37","author":"Mansour","year":"2024","journal-title":"J. Aerosol Med. Pulm. Drug Deliv."},{"issue":"1","key":"10.1016\/j.pscia.2026.100136_bib8","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.ijpharm.2018.07.007","article-title":"Dosing challenges in respiratory therapies","volume":"548","author":"Yeung","year":"2018","journal-title":"Int. J. Pharm."},{"issue":"2","key":"10.1016\/j.pscia.2026.100136_bib9","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/jps.23775","article-title":"Development and comparison of new high-efficiency dry powder inhalers for carrier-free formulations","volume":"103","author":"Behara","year":"2014","journal-title":"J. Pharmaceut. Sci."},{"issue":"9","key":"10.1016\/j.pscia.2026.100136_bib10","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1183\/09031936.97.10092127","article-title":"Airway deposition and airway effects of antiasthma drugs delivered from metered-dose inhalers","volume":"10","author":"Pauwels","year":"1997","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.pscia.2026.100136_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2019.105059","article-title":"Real-life budesonide and formoterol dose emission from the medium and high strength fixed dosed combinations in a spiromax\u00ae dry powder inhaler using inhalation profiles from patients with chronic obstructive pulmonary disease","volume":"139","author":"Bagherisadeghi","year":"2019","journal-title":"Eur. J. Pharmaceut. Sci."},{"issue":"12","key":"10.1016\/j.pscia.2026.100136_bib12","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1007\/s11095-022-03363-2","article-title":"Advancements in particle engineering for inhalation delivery of small molecules and biotherapeutics","volume":"39","author":"Chang","year":"2022","journal-title":"Pharm. Res."},{"issue":"7","key":"10.1016\/j.pscia.2026.100136_bib13","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1111\/resp.14046","article-title":"Pharmacological treatment of stable chronic obstructive pulmonary disease","volume":"26","author":"Singh","year":"2021","journal-title":"Respirology"},{"issue":"6","key":"10.1016\/j.pscia.2026.100136_bib14","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1080\/14740338.2018.1472233","article-title":"The safety of indacaterol for the treatment of COPD","volume":"17","author":"Metaxas","year":"2018","journal-title":"Expert Opin. Drug Saf."},{"issue":"1","key":"10.1016\/j.pscia.2026.100136_bib15","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1186\/s12931-020-01501-1","article-title":"Lung function, pharmacokinetics, and tolerability of inhaled indacaterol maleate and acetate in asthma patients","volume":"21","author":"Miller","year":"2020","journal-title":"Respir. Res."},{"issue":"3","key":"10.1016\/j.pscia.2026.100136_bib16","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1080\/14656566.2017.1285906","article-title":"Tiotropium for the treatment of asthma in adolescents","volume":"18","author":"Hamelmann","year":"2017","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.pscia.2026.100136_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2025.125696","article-title":"Formulation of a dry powder for inhalation combining ciclesonide and indacaterol maleate using spray drying","volume":"678","author":"Bya","year":"2025","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.pscia.2026.100136_bib18","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.pupt.2017.04.002","article-title":"Role of dual bronchodilators in COPD: a review of the current evidence for indacaterol\/glycopyrronium","volume":"45","author":"Ficker","year":"2017","journal-title":"Pulm. Pharmacol. Therapeut."},{"issue":"5","key":"10.1016\/j.pscia.2026.100136_bib19","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1164\/ajrccm.164.5.2007006","article-title":"Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease","volume":"164","author":"Dahl","year":"2001","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"7","key":"10.1016\/j.pscia.2026.100136_bib20","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/j.rmed.2010.02.017","article-title":"Combining tiotropium and salmeterol in COPD: effects on airflow obstruction and symptoms","volume":"104","author":"van Noord","year":"2010","journal-title":"Respir. Med."},{"issue":"4","key":"10.1016\/j.pscia.2026.100136_bib21","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/resp.13651","article-title":"Indacaterol\/glycopyrronium versus tiotropium or glycopyrronium in long-acting bronchodilator-na\u00efve COPD patients: a pooled analysis","volume":"25","author":"Muro","year":"2020","journal-title":"Respirology"},{"issue":"1","key":"10.1016\/j.pscia.2026.100136_bib22","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ijpharm.2016.03.004","article-title":"Dispersibility of lactose fines as compared to API in dry powders for inhalation","volume":"504","author":"Thalberg","year":"2016","journal-title":"Int. J. Pharm."},{"issue":"1","key":"10.1016\/j.pscia.2026.100136_bib23","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0032-5910(75)80021-0","article-title":"Ordered mixing: a new concept in powder mixing practice","volume":"11","author":"Hersey","year":"1975","journal-title":"Powder Technol."},{"key":"10.1016\/j.pscia.2026.100136_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114527","article-title":"Recent developments in lactose blend formulations for carrier-based dry powder inhalation","volume":"189","author":"Hebbink","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"2","key":"10.1016\/j.pscia.2026.100136_bib25","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ijpharm.2016.05.057","article-title":"From single excipients to dual excipient platforms in dry powder inhaler products","volume":"514","author":"Shur","year":"2016","journal-title":"Int. J. Pharm."},{"issue":"6","key":"10.1016\/j.pscia.2026.100136_bib26","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1080\/03639045.2017.1287719","article-title":"Co-milled API-lactose systems for inhalation therapy: impact of magnesium stearate on physico-chemical stability and aerosolization performance","volume":"43","author":"Lau","year":"2017","journal-title":"Drug Dev. Ind. Pharm."},{"issue":"1","key":"10.1016\/j.pscia.2026.100136_bib27","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ijpharm.2016.02.017","article-title":"Statistical tools and control of internal lubricant content of inhalation grade HPMC capsules during manufacture","volume":"503","author":"Ayala","year":"2016","journal-title":"Int. J. Pharm."},{"issue":"3","key":"10.1016\/j.pscia.2026.100136_bib28","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1089\/089426803769017659","article-title":"Next generation pharmaceutical impactor (A new impactor for pharmaceutical inhaler testing). Part I: design","volume":"16","author":"Marple","year":"2003","journal-title":"J. Aerosol Med."},{"key":"10.1016\/j.pscia.2026.100136_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.124549","article-title":"New theory to explain the effect of lactose fines on the performance of adhesive mixtures for inhalation","volume":"663","author":"Thalberg","year":"2024","journal-title":"Int. J. Pharm."},{"issue":"1","key":"10.1016\/j.pscia.2026.100136_bib30","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0378-5173(02)00359-9","article-title":"The influence of relative humidity on particulate interactions in carrier-based dry powder inhaler formulations","volume":"246","author":"Price","year":"2002","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.pscia.2026.100136_bib31","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.addr.2014.04.004","article-title":"Technological and practical challenges of dry powder inhalers and formulations","volume":"75","author":"Hoppentocht","year":"2014","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"9","key":"10.1016\/j.pscia.2026.100136_bib32","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.4187\/respcare.05501209","article-title":"Dry powder inhaler formulation","volume":"50","author":"Telko","year":"2005","journal-title":"Respir. Care"},{"issue":"2","key":"10.1016\/j.pscia.2026.100136_bib33","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0378-5173(03)00250-3","article-title":"Air classifier technology (ACT) in dry powder inhalation. Part 1. Introduction of a novel force distribution concept (FDC) explaining the performance of a basic air classifier on adhesive mixtures","volume":"260","author":"de Boer","year":"2003","journal-title":"Int. J. Pharm."},{"issue":"1","key":"10.1016\/j.pscia.2026.100136_bib34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2010.03.017","article-title":"Formulation strategy and use of excipients in pulmonary drug delivery","volume":"392","author":"Pilcer","year":"2010","journal-title":"Int. J. Pharm."},{"issue":"4","key":"10.1016\/j.pscia.2026.100136_bib35","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1021\/acs.molpharmaceut.8b00007","article-title":"Characterizing the surface roughness length scales of lactose carrier particles in dry powder inhalers","volume":"15","author":"Tan","year":"2018","journal-title":"Mol. Pharm."},{"issue":"2","key":"10.1016\/j.pscia.2026.100136_bib36","doi-asserted-by":"crossref","first-page":"246","DOI":"10.3390\/pharmaceutics18020246","article-title":"Advancing dry powder inhalers: a complete workflow for carrier-based formulation development","volume":"18","author":"Amorim","year":"2026","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.pscia.2026.100136_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejpb.2025.114740","article-title":"Enhancing blending efficiency and in vitro aerosol performance of low-dose inhalable dry powders with spray freeze dried microparticles","volume":"212","author":"Zhang","year":"2025","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"4","key":"10.1016\/j.pscia.2026.100136_bib38","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics17040486","article-title":"Nanoparticle-based dry powder inhaler containing ciprofloxacin for enhanced targeted antibacterial therapy","volume":"17","author":"Party","year":"2025","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.pscia.2026.100136_bib39","article-title":"Correlation of brittle matrix powder properties to aerodynamic performance of inhaled nintedanib made by thin-film freezing","volume":"79","author":"Praphawatvet","year":"2023","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"10.1016\/j.pscia.2026.100136_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.121122","article-title":"Inhaled Edoxaban dry powder inhaler formulations: development, characterization and their effects on the coagulopathy associated with COVID-19 infection","volume":"608","author":"Rashid","year":"2021","journal-title":"Int. J. Pharm."},{"issue":"9","key":"10.1016\/j.pscia.2026.100136_bib41","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.3390\/pharmaceutics17091089","article-title":"Comparative in vitro deposition analysis of formoterol, glycopyrronium, and tiotropium delivered via capsule-based DPI","volume":"17","author":"Sikora","year":"2025","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.pscia.2026.100136_bib42","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ejps.2017.03.035","article-title":"Effect of maximum inhalation flow and inhaled volume on formoterol drug deposition in-vitro from an Easyhaler\u00ae dry powder inhaler","volume":"104","author":"Abadelah","year":"2017","journal-title":"Eur. J. Pharmaceut. Sci."},{"issue":"1","key":"10.1016\/j.pscia.2026.100136_bib43","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1208\/s12249-017-0841-y","article-title":"Study of the emitted dose after two separate inhalations at different inhalation flow rates and volumes and an assessment of aerodynamic characteristics of indacaterol Onbrez breezhaler\u00ae 150 and 300 \u03bcg","volume":"19","author":"Abadelah","year":"2018","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.pscia.2026.100136_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119984","article-title":"Spray drying lactose from organic solvent suspensions for aerosol delivery to the lungs","volume":"591","author":"Ke","year":"2020","journal-title":"Int. J. Pharm."},{"issue":"8","key":"10.1016\/j.pscia.2026.100136_bib45","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1080\/03639045.2020.1788067","article-title":"Solid-state interaction of ibuprofen with magnesium stearate and product characterization thereof","volume":"46","author":"Stojanovska Pecova","year":"2020","journal-title":"Drug Dev. Ind. Pharm."}],"container-title":["Pharmaceutical Science Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2773216926000292?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2773216926000292?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T22:01:05Z","timestamp":1786485665000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2773216926000292"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":45,"alternative-id":["S2773216926000292"],"URL":"https:\/\/doi.org\/10.1016\/j.pscia.2026.100136","relation":{},"ISSN":["2773-2169"],"issn-type":[{"value":"2773-2169","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development and characterization of an Indacaterol\/Tiotropium Bromide composite dry powder inhalation formulation for COPD","name":"articletitle","label":"Article Title"},{"value":"Pharmaceutical Science Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pscia.2026.100136","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of Shandong University.","name":"copyright","label":"Copyright"}],"article-number":"100136"}}